ZBD(SH:603567) Zhong Guo Jing Ji Wang·2025-09-22 04:51Core Insights - The traditional Chinese medicinal materials trading industry faces challenges such as fragmentation, lack of standardization, and modernization, leading to issues like price discrepancies and quality inconsistencies, which affect medication safety and industry reputation [1] - The Bozhou Chinese Medicinal Materials Commodity Trading Center is launching an upgraded "Bulk Chinese Medicinal Materials Trading Platform" during the 2025 International (Bozhou) Pharmaceutical Expo, aiming to reshape the industry ecosystem with innovative mechanisms [1][2] Industry Development - Recent government policies, including the "14th Five-Year Plan for Traditional Chinese Medicine Development," are promoting the standardization and high-quality development of the Chinese medicinal materials industry [2] - Bozhou, as the largest distribution center for Chinese medicinal materials in China, is undergoing a transformation that has garnered significant industry attention [2] Trading Platform Innovations - The new trading platform introduces a warehouse receipt trading model, enhancing the standardization and efficiency of transactions while addressing traditional pain points such as low efficiency and high costs [2][3] - The platform's full online process and electronic warehouse receipt system aim to improve transparency and reduce costs in the supply chain [2][3] Mechanisms Addressing Industry Pain Points - The platform focuses on online, standardized, and financialized trading to tackle issues like price chaos, quality concerns, high costs, and financing difficulties [3] - Financial support services such as accounts receivable financing and order financing are designed to alleviate cash flow issues for small and medium-sized businesses [3] - Collaboration with local governments to implement GAP certification and traceability systems aims to enhance quality control and reduce overall costs in the supply chain [3] Innovative Trading Mechanism - The "spot + warehouse receipt" trading mechanism allows for standardized storage and multiple circulations of medicinal materials, significantly lowering transaction costs and improving efficiency [4] - The platform anticipates achieving transaction volumes of at least 300 million yuan in 2025, 3 billion yuan in 2026, and over 10 billion yuan in 2027, with a long-term goal of exceeding 100 billion yuan in annual transactions within five years [4] Strategic Integration - The trading platform serves as a strategic initiative for Zhenbaodao Pharmaceutical to enhance supply chain control, stabilize product quality, and reduce cost fluctuations [5] - By integrating high-quality resource areas and establishing a traceable raw material supply system, the company aims to improve procurement negotiation capabilities and inventory management flexibility [5] - The platform is positioned as a key strategy for Zhenbaodao Pharmaceutical to innovate traditional trading methods and tap into supply chain finance, potentially creating significant growth opportunities in the traditional Chinese medicine sector [5]